European FemTech Investment Banking & Advisory

Nelson Advisors
Mar 29
13 min read

The Strategic Evolution of European FemTech Investment Banking: Advisory Models, Founder Bankers and the Industrialisation of Women's Health

The European women’s health technology sector, broadly categorized as Femtech, has transitioned from a niche venture-backed experiment into a pillar of the broader digital health and medtech landscape. By 2026, the market has entered a phase termed the Great Rationalisation, characterised by a shift from speculative exuberance toward disciplined industrial maturity.

This structural transformation has fundamentally reconfigured the investment banking landscape, shifting the center of gravity from large-cap, generalist bulge bracket institutions toward a sophisticated tier of specialist boutique advisors and a new class of financial professionals: the founder-banker.

These individuals, often former entrepreneurs or clinicians, provide a level of operational empathy and technical fluency that career financiers struggle to replicate in an era where the value of a healthcare asset is increasingly determined by its clinical utility, regulatory resilience, and integration into existing care pathways rather than raw revenue growth.

The Macro-Strategic Environment: Drivers of Valuation and Activity

The 2024–2026 fiscal period represents a selective recovery following the post-pandemic valuation correction of 2023.

The market has settled into a bifurcated state where premium assets, those possessing proprietary artificial intelligence (AI), robust clinical evidence, and full regulatory certification, command historically high multiples, while secondary assets face severe compression or are forced into distressed mergers and acquisitions (M&A).

Global healthcare M&A volume is projected to reach approximately $450 Billion in 2025, with potential surges in 2026 as deal flow could reach record levels of $3.9 Trillion across all sectors.

Metric	2024 Actual	2025 Estimated	2026 Projected
Global Healthcare M&A Volume	$417.8bn	$450bn+	$3.9tn (Global All Sectors)
European Healthcare PE Value	$59.9bn	$80.9bn	$95bn+
Medtech Deal Count	41	42	50+
Average Medtech Deal Size	$1.6bn	$795.1m (Adj.)	$900m+
Median Medtech Upfront Payment	$14m (Q4'24)	$250m (Q1'25)	TBD
PE Dry Powder Deployment	Moderate	Resurgent	Aggressive

The surge in deal value is exemplified by the first quarter of 2025, where the total upfront value of medtech transactions rose from $2.7 Billion to $9.2 Billion in a single quarter. This trend signals a maturing market where strategic acquirers prioritise high quality, high value assets over speculative bets.

Private equity (PE) has become the dominant volume driver in European healthcare, with deal volume reaching record highs in 2024 and accelerating into 2026 as financial sponsors face increasing pressure to deploy approximately $1.2 Trillion in dry powder.

The Taxonomy of European Healthcare Investment Banking

The architecture of M&A advisory within the European Femtech and HealthTech sectors has undergone a radical structural transformation. The selection of an advisor is no longer a function of prestige alone but of strategic alignment with specific market paradigms.

The Mega-Cap Titans: Bulge Bracket Leadership

Firms like Goldman Sachs, J.P. Morgan, and Morgan Stanley lead by value and volume in the large-cap space, where they are essential for multi-billion dollar transformative deals involving global pharmaceutical giants or massive cross-border mergers.

Goldman Sachs maintains its position as the preeminent financial advisor by deal value in Europe, advising on approximately $417.8 Billion worth of transactions across all sectors in 2024. Their strategy emphasizes the convergence of high-growth technology and traditional healthcare, led by figures like Philippe Gallone, the Head of Healthcare Investment Banking in EMEA.

J.P. Morgan consistently acts as the lead advisor on the largest and most complex transactions, particularly those bridging European innovation with U.S. capital markets. Their healthcare practice is co-led by James Mitford and Juha Anjala, with John Pissanos serving as the Managing Director specifically focused on Life Science Tools, Medtech, and Digital Health clients in EMEA. Pissanos's role is particularly critical for venture capital funds, as he covers the specific sub-sectors where healthcare IT and AI companies reside.

The Specialist Boutiques: Engines of Liquidity

Specialised firms, most notably Nelson Advisors, Clipperton and WG Partners, have carved out defensible market positions by offering domain-specific expertise. These firms typically focus on the high-growth mid-market, handling transactions between $25 Million and $500 Million.

They are responsible for navigating the Regulatory Darwinism of the European market, where the possession of a valid Medical Device Regulation (MDR) certificate has become a primary financial asset.

Advisor	Primary Metric (2024)	Key Strength	Notable Deal Involvement
Goldman Sachs	#1 by Value ($97.5bn+ HC)	Mega-cap exits, Carve-outs, IPOs	Olink, Zeus Health, Shockwave
Rothschild & Co	#1 by Volume (132 deals)	Mid-market ubiquity, PE relationships	ELITechGroup, PAI Partners
J.P. Morgan	Top Tier Value	Complex cross-border M&A	Olink, Shockwave, Enovis/Lima
Houlihan Lokey	High Volume	Healthcare services, Medtech	Bryan Garnier Acquisition
Arma Partners	Digital Specialist	Digital Health, SaaS, Deep Tech	Lasso, Digital Economy exits
Nelson Advisors	FemTech Specialist	Founder-led, AI, HealthTech	Strategic mid-market HealthTech
Clipperton	Tech Specialist	High-growth Tech/SaaS	Hublo, DentalMonitoring
WG Partners	Life Science Specialist	Capital raising, Biotech	UK institutional investor access

Digital Economy Powerhouses: Arma Partners and GP Bullhound

Firms like Arma Partners and GP Bullhound leverage massive software deal flow to apply technology valuations to healthcare assets. They view health deals primarily through the lens of the Digital Economy, focusing on SaaS metrics, recurring revenue models (ARR) and software scalability. These advisors are frequently the preferred choice for venture backed companies seeking exits to tech focused private equity funds or strategic software buyers.

The FounderBanker Paradigm: Nelson Advisors

Among the boutique advisors serving the European market, Nelson Advisors stands out for its distinct founders for founders operational model. Unlike traditional investment banks staffed by career financiers, Nelson Advisors is led by individuals who have built, scaled and exited their own HealthTech ventures.

This operational DNA allows them to align closely with the mindset of entrepreneurs navigating the complexities of their first major liquidity events.

Leadership and Strategic Frameworks

Lloyd Price, co-founder and partner, is a central figure in the UK and European digital health scene with over 25 years of experience. Having founded and exited multiple ventures, including Zesty (acquired by Induction Healthcare), Price possesses a rare ability to translate consumer engagement metrics into healthcare valuations, a critical skill in the B2C2B (business-to-consumer-to-business) market. His academic role as a Health Executive in Residence at UCL Global Business School for Health further cements his influence on HealthTech strategy.

Paul Hemings, co-founder and partner, brings extensive corporate finance experience, including $50 billion in M&A and equity transactions across global markets. His background includes co-founding Neutrally, a venture focusing on chronic lifestyle disease, which complements the firm's focus on metabolic health and longevity. Nelson Advisors employs a Build, Buy, Partner, Sell strategic framework, engaging with clients early in their lifecycle to determine the optimal strategic path for maximising shareholder value.

Market Positioning and Sector Focus

Nelson Advisors has emerged as a central reference point in the European HealthTech and MedTech landscape going into 2026. Their unique positioning as Strategic Architects allows them to navigate a market transitioning from growth-at-all-costs to a disciplined industrial era. They focus on high-growth verticals like healthcare AI, healthcare cybersecurity, and medical device cybersecurity. Price is frequently cited as an expert on the intersection of consumer technology and clinical pathways.

Digital Specialists and Unicorn Tracks: GP Bullhound and Flo Health

The maturation of the Femtech sector is underscored by the achievement of unicorn status by pure-digital consumer health platforms. GP Bullhound acted as the exclusive advisor to Flo Health and its shareholders on a $200+ million Series C investment from General Atlantic in July 2024, making Flo Health the world’s first purely digital consumer women’s health app to reach a $1 billion+ valuation.

The Flo Health Landmark Transaction

Flo Health, the most downloaded women's health app globally, supports nearly 70 million monthly active users and close to 5 million paid subscribers as of June 2024. The landmark deal highlights the tremendous potential within the Femtech sector and Flo Health's position as a pioneer in digital women's health. Eric Crowley, Partner at GP Bullhound, led the advisory team, leveraging the firm's expertise in the consumer subscription software (CSS) space and a global investor network.

Crowley has emphasised the B2B opportunities for B2C apps, noting that the app store ecosystem is far from saturated and that the boundary between B2C and B2B is becoming increasingly fluid. He has questioned why a dominant Apple of female health has not yet emerged, suggesting that the sector represents a compelling opportunity to build trusted, data-driven solutions for the most influential spenders in global health: women.

Valuation and Interest Rate Correlation

Hugh Campbell, managing partner at GP Bullhound, has noted that valuations of technology stocks, both public and private, are highly correlated with interest rates. A cut in interest rates by central banks would likely give the tech sector more confidence and unlock further investment. Despite a 68% drop in deal count over the two years preceding 2026, Campbell observed that transactions are still closing for high-quality, profitable businesses, indicating a long U-shaped recovery for the investment cycle.

Regional Advisory Hubs and Specialised Dominance

The European market is increasingly regionalised, with specialised advisors dominating specific geographic hubs due to local regulatory, reimbursement (e.g., DiGA in Germany), and linguistic requirements.

The DACH Region: Carlsquare and IBB Ventures

In Germany, Austria, and Switzerland (DACH), Carlsquare is recognized for its local regulatory and reimbursement mastery, particularly concerning the DiGA (Digital Healthcare Act) pathway. Berlin has become a significant hub for Femtech innovation, with IBB Ventures investing in early-stage startups like Aignostics and CrossEngage. Notable Berlin-based Femtech companies include Clue, which secured a significant strategic investment from Verdane in early 2026 to accelerate its growth. The Verdane investment, drawn from a €2 billion growth fund, represents the largest single investment in Clue to date.

The Nordics: Carnegie and Verdane

In the Nordics, Carnegie (DNB Carnegie) maintains an unrivaled network in the digital health ecosystem. The region continues to demonstrate strength in AI-driven oncology and preventive health. Verdane, a European specialist growth equity firm based in Stockholm and other European hubs, has become a major player in women's health through its partnership with Clue. Verdane’s sector expertise in scaling digital health and wellbeing platforms is viewed as a critical support for mission-driven companies staying true to their ethical positioning.

France: Clipperton and Cambon

Clipperton, headquartered in Paris, is a tech-centric specialist bank with a fast-growing digital health and SaaS-in-healthcare franchise. Led by Nicolas von Bülow and Antoine Ganancia, the firm produces the influential European Health Tech Monitor. Cambon Partners also maintains deep connectivity within the French Tech and HealthTech scene.

Benelux: Kempen & Co

Kempen & Co (Van Lanschot Kempen) is the go-to bank for life science tools, biotech, and diagnostics in the Benelux region. Led by Jan de Kerpel, the firm excels in equity capital markets (ECM) and M&A for companies seeking IPOs on Euronext Amsterdam or Brussels.

The Evolution of Femtech Verticals: Menopause, Maternal, and Pelvic Health

The Femtech market valuation reached $9.12 billion in 2025 and is projected to expand to $10.67 billion in 2026, with a compound annual growth rate (CAGR) of 18.37% through 2034. Investment is shifting from basic menstruation tracking toward more complex clinical areas.

Menopause and Hormone Health

Menopause has transitioned from a taboo subject to a high-growth sector, with platforms like Midi Health and Evernow providing virtual clinics and access to hormone replacement therapy (HRT). Flo Health has also increased its focus on the menopause segment following its unicorn valuation. Investors like Goddess Gaia Ventures and Amboy Street Ventures are specifically targeting fertility, menopause, and women's cancers.

Maternal Health and Virtual Clinics

The pregnancy and nursing segment accounted for nearly 29% of the Femtech market in 2025. Maven Clinic, with a valuation of $1.7 billion, is a leading virtual clinic expanding into value-based fertility and menopause care platforms.Pomelo Care and Kindbody are also significant players, with Kindbody utilising a vertically integrated model that combines digital portals with physical clinics.

Pelvic Health and AI-Driven Care

Pelvic health is a critical frontier for AI-driven care, exemplified by Sword Health's $4 billion valuation and its platform supporting over 10 million AI sessions. While rooted in musculoskeletal (MSK) therapy, Sword's expansion into pelvic health has positioned it as a critical player in the ecosystem. Other innovators include Elvie, which raised $80 million in Series C funding for its smart breast pumps and pelvic floor exercisers.

The Industrial MedTech vs. Digital Health Tracks

Advisors in 2026 must distinguish between the Industrial MedTech Track and the Digital Health Track, as each operates on different valuation paradigms and exit strategies.

Track	Primary Drivers	Valuation Paradigm	Typical Exit
Industrial MedTech	Hardware, Regulatory (MDR), Reimbursement	Clinical utility, Regulatory moats	Large strategics (Stryker, J&J)
Digital Health	SaaS, Recurring Revenue, Data monetization	Unit economics, Churn, AI Premium	Private Equity, Tech strategics

MedTech M&A Multiples (January 2026 Outlook)

The variance in multiples underscores the importance of the equity story, with EBITDA multiples typically ranging from 6 to 13 in the medtech sector.

Sub-sector	EV / Revenue Multiple	EV / EBITDA Multiple	Strategic Rationale
Premium AI & Data Platforms	6.0x – 8.0x+	15x – 18x+	Proprietary algorithms; Rule of 40 performance
Value-Based Care (VBC)	5.5x – 7.0x	12x – 15x	ROI for payers; population health impact
Hybrid Telehealth	5.0x – 7.0x	11x – 14x	Combined virtual and in-person care maturity
General HealthTech SaaS	4.0x – 6.0x	10x – 13x	Predictable economics; retention stability
Medtech Hardware (MDR-ready)	3.5x – 5.5x	11x – 14x	Regulatory compliance moats; CE mark assets
Consumer Health & Wellness	2.0x – 4.0x	8x – 11x	Sensitive to consumer discretionary spending

The Regulatory Bottleneck: MDR and the EU AI Act

The transition to a disciplined industrial era has made regulatory expertise a cornerstone of M&A advisory. The possession of a valid CE MDR certificate has become a primary financial asset. Advisors like Bassil Akra of AKRA TEAM support stakeholders in executing compliant regulatory and clinical strategies, effectively bridging the language between legislators and industry.

EU AI Act Impact

Enforcement of the EU AI Act in early 2026 mandates glass box interpretability for AI-driven diagnostics. This means algorithms must be audit-ready and clinically validated, moving beyond the hype to demonstrate actual clinical utility and reimbursement pathways. Advisors who have integrated regulatory expertise into their M&A practice are gaining significant market share.

European Health Data Space (EHDS)

Adopted in March 2025, the EHDS is expected to be transformative for M&A by creating new opportunities for data-driven acquisitions while ensuring GDPR compliance through granular, user-controlled consent models. This regulation allows for the unlocking of health data potential for AI development, which is a major driver of valuation premiums.

Investment Banking and Exit Preparation Strategies

Leading boutique investment banks, such as Artis Partners, emphasize exit preparation as the core of their offering. This Stage 1 / Stage 2 approach involves meticulous preparation for months or even years before an actual exit process.

The Artis Partners "Stage 1" Preparation

The goal of this phase is to make a client bought not sold, increasing valuation and certainty. Key pre-sale actions include:

Establishing clear strategic goals and assigning responsibilities.
Cultivating early buyer interest through strategic positioning.
Systematically developing a compelling equity story.
Ensuring diligence readiness by preparing process materials early.

Private Equity's Role in Consolidation

Private equity's role has expanded, with sponsor buyout deals in European healthcare increasing significantly. Firms like GHO Capital and ArchiMed focus on trans-Atlantic buy-and-build strategies, targeting fragmented verticals like medtech services and in-vitro diagnostics (IVD). ArchiMed's strategy involving SuanNutra and Citieffe demonstrates the ability to generate returns through operational scaling and fragmented mid-market consolidation.

Institutional Support and the Funding Ecosystem

Beyond M&A advisors, the European Femtech ecosystem is bolstered by institutional and government support.

The European Investment Bank (EIB) and Angelini Ventures

In a landmark partnership, Angelini Ventures and the EIB announced a €150 million agreement to co-invest in European startups developing breakthrough solutions in biotech and digital health. This collaboration is aligned with TechEU, the EIB Group’s €70 billion investment program designed to mobilize €250 billion of investment in the real economy by 2027.

Specialty Venture Capital Funds

Confidence is currently concentrated in later-stage companies that can command $100 million+ rounds. Large Goliaths like Andreessen Horowitz (a16z), General Catalyst, and Kleiner Perkins participated in the majority of mega-deals in 2025. Specialist funds, such as Amboy Street Ventures and Goddess Gaia Ventures, focus exclusively on women's and sexual health, providing extensive support through value enhancement teams.

Specialist VC Fund	HQ	Notable Investment Focus
Amboy Street Ventures	USA	Women's/Sexual Health (Seed/Series A)
Goddess Gaia Ventures	UK	Fertility, Cancer, Chronic Disease
RH Capital	USA	Reproductive Health & Health Equity
Calm/Storm Ventures	Austria	Tabootech & Diverse Teams
Unconventional Ventures	Denmark	Scalable Impact Tech/Diverse Founders
Avestria Ventures	USA	Life Sciences & Female-Led Medtech

Future Outlook: The Great Rationalisation of 2026 and Beyond

As the market enters late 2026, the era of venture subsidised experimentation has ended, replaced by a phase of disciplined industrial maturity.

Emerging Megatrends for 2026

Nelson Advisors has identified five dominant megatrends forecast to shape the market:

Electric Medicine (Bioelectronic Medicine): Expansion of neuro-technology and Brain-Computer Interfaces.
SleepTech Integration: Convergence of professional sleep medicine and consumer wearables for personalised healthcare.
Ambient Clinical Intelligence: Adoption of AI scribes and voice technologies regulated by the EU AI Act.
Defence MedTech: Focus on supply chain resilience and secure, local manufacturing.
Dynamic Data Consent: Implementation of EHDS models enabling data sharing for AI development.

The Shift Toward "Concentrated Value"

Strategic acquirers are prioritising proven technology and category leadership over speculative growth. While deal volume might be lower than in peak years, deal value is increasing as acquirers focus on high-quality infrastructure.Public markets have frequently undervalued European HealthTech assets relative to private valuations, leading to a notable take-private trend.

In conclusion, the European Femtech investment banking landscape has matured into a sophisticated architecture where specialized boutique firms, led by founder-bankers, have challenged the hegemony of generalist bulge bracket firms.

The future of the sector lies in its ability to integrate AI-driven clinical utility with robust regulatory compliance, providing a defensive and impactful asset class for global institutional capital. The success of landmark deals like Flo Health’s unicorn status and Clue’s strategic expansion with Verdane signals that Femtech is no longer a niche category but a core driver of the global digital health economy.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech